Recent advances in chronic lymphocytic leukemia

Vyas, Nina; Hassan, Ali F.

doi:10.4103/0019-509x.98940

Cited by 7 publications

(3 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 Chemoimmunotherapy represents the standard therapy for the majority of CLL patients, as this treatment modality typically offers durable responses and excellent overall survival benefits. 2 However, a subset of CLL patients with deletion of the short-arm of chromosome 17 (17p-) are refractory to chemoimmunotherapy, resulting in poor outcomes.…”

Section: Introductionmentioning

confidence: 99%

p53-independent ibrutinib responses in an Eμ-TCL1 mouse model demonstrates efficacy in high-risk CLL

Lee

Gallardo

et al. 2016

Blood Cancer Journal

View full text Add to dashboard Cite

Deletion of the short-arm of chromosome 17 (17p-) is one of the most critical genetic alterations used in chronic lymphocytic leukemia (CLL) risk stratification. The tumor suppressor TP53 maps to this region, and its loss or mutation accelerates CLL progression, hampers response to chemotherapy and shortens survival. Although florescent in situ hybridization analyses for 17p deletions are routinely performed during clinical diagnoses, p53 mutational status is often unexamined. Given the limited clinical data that exists for frontline treatment of patients with CLL harboring TP53 mutations, there is a need to understand the biology of CLL with TP53 mutations and identify treatment strategies for this subset of patients. Herein, we used a CLL mouse model (Eμ-TCL1) harboring one of the most common TP53 hot-spot mutations observed in CLL (p53R172H, corresponding to p53R175H in humans) to evaluate its impact on disease progression, survival, response to therapy and loss of the remaining wild-type Trp53 allele following ibrutinib treatment. We show that ibrutinib was effective in increasing survival, activating cellular programs outside the p53 pathway and did not place selective pressure on the remaining wild-type Trp53 allele. These data provide evidence that ibrutinib acts as an effective treatment for aggressive forms of CLL with TP53 mutations.

show abstract

Section: Introductionmentioning

confidence: 99%

p53-independent ibrutinib responses in an Eμ-TCL1 mouse model demonstrates efficacy in high-risk CLL

Lee

Gallardo

et al. 2016

Blood Cancer Journal

View full text Add to dashboard Cite

show abstract

“…The occurrence of CLL, B-cell type, is thought to be distinctly uncommon in patients younger than 40 years of age [1]. CLL was largely considered to be a disease of slow progression [2]. In this case the patient was just 37 years old when he presented with CLL in advanced stage.…”

Section: Discussionmentioning

confidence: 92%

A Case of Early Ocular Manifestation of Maculopathy in a 37 year Old Male Patient of CLL

Mehdi

Tandon

Khan

et al. 2014

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

B cell chronic lymphocytic leukemia (CLL) also called chronic lymphocytic leukemia is a disease of elderly, but in rare cases it can occur in young adults. Majority of patients present with no specific symptoms, and CLL is suspected on the basis of high total and relative lymphocyte counts, discovered on routine blood examination. This patient was referred from medicine outpatient in our institute, Era's Lucknow Medical College & Hospital for routine complete blood count. His total leukocyte count came out to be alarmingly high. The general blood picture and bone marrow examinations were consistent with CLL. On immunophenotyping CD5 and CD23 were positive. His cervical lymph nodes biopsy was reported as a case of CLL/small lymphocytic lymphoma. On his complaint of hazy vision his funduscopy revealed maculopathy. This makes our case a unique and rare one, as maculopathy in a young patient of CLL has not yet been reported from India.

show abstract

“…To ensure consistency in terminology throughout this article, the term CLL will be used to encompass both CLL and SLL. CLL is an indolent malignancy characterized by increased production of mature B-lymphocytes in bone marrow, blood cells, and lymph nodes [ 6 ]. The majority of patients are asymptomatic at diagnosis, 10% of patients present with B symptoms, most patients have enlarged and palpable lymphadenopathy, and 20% to 50% of patients present with hepatosplenomegaly on examination [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

A Rare Case of Recurrent Cutaneous Non-Hodgkin’s Lymphoma in the Extremity: Long-Term Follow-Up and Review of the Literature Written With the Assistance of ChatGPT

Dejong¹,

Gill²,

Lam³

et al. 2023

Cureus

View full text Add to dashboard Cite

Cutaneous involvement of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is uncommon. We report on a 71-year-old male with a history of CLL of the skin in the distal extremities. The patient presented with eruptions of new lesions on the toes of his feet bilaterally, causing significant pain that limited his mobility. Cutaneous involvement of CLL is a rare presentation, and management recommendations are largely based on case reports with limited follow-up. Furthermore, assessing the duration of response, response rates, and correct sequencing of treatment is difficult due to variable use and doses of treatment. The case was treated in 2001 when newer systemic treatments were not available. Therefore, the results can also be directly related to local treatments. Based on a literature review and this case, this report provides insight into the benefits and risks of local treatment for cutaneous involvement of CLL in the extremities and how radiation can be sequenced with other options such as surgical excision and chemotherapy.

show abstract

Recent advances in chronic lymphocytic leukemia

Cited by 7 publications

References 57 publications

p53-independent ibrutinib responses in an Eμ-TCL1 mouse model demonstrates efficacy in high-risk CLL

p53-independent ibrutinib responses in an Eμ-TCL1 mouse model demonstrates efficacy in high-risk CLL

A Case of Early Ocular Manifestation of Maculopathy in a 37 year Old Male Patient of CLL

A Rare Case of Recurrent Cutaneous Non-Hodgkin’s Lymphoma in the Extremity: Long-Term Follow-Up and Review of the Literature Written With the Assistance of ChatGPT

Contact Info

Product

Resources

About